Rigontec

Exit

Rigontec GmbH, is a privately held biopharmaceutical company developing RNA-based immunotherapeutics for the treatment of cancer and viral diseases.

Rigontec focus on the development of synthetic ligands of a novel receptor of the innate immune system, Retinoic acid Inducible Gene I (RIG-I), which recognizes viral RNA. RNA motifs that activate RIG-I promote the destruction of diseased cells and the induction of a lasting immune memory thereby treating and preventing recurrence of disease.

Rigontec’s, a proprietary first-in-class product targeting RIG-I, is currently being evaluated for development in several cancer types including melanoma and prostate cancer. ImOl100 is a chemically synthesized mimic of the natural ligand of RIG-I with improved safety and drug like properties. In various preclinical models, ImOl100 has demonstrated substantial tumor regression and systemic anti-tumor activity including long-term protection against tumor rechallenge. Rigontec’s technology also allows the design of pipeline candidates with additional gene silencing and inhibitory activities. Rigontec is financed by top-tier VC investors and is seeking to realize the full potential of its technology by developing an internal pipeline into the clinic.

Press releases

Press
6. September 2016
Rigontec Raises Additional €15M in Extended Series A to Advance Novel RIG-I Targeted Immuno-Oncology Therapeutics
Rigontec, the leader in RIG-I targeting RNA therapeutics, today announced that it has secured EUR 15 million in a third and final closing of its Series A round. The financing represents additional capital from current investors Boehringer Ingelheim Venture Fund, Forbion Capital Partners, High-Tech Gründerfonds (HTGF), NRW.BANK, MP Healthcare Venture Management, Sunstone Capital and Wellington Partners Life Sciences. The funding will advance the ongoing development of Rigontec’s RIG-I agonist
 
Press
24. March 2015
Rigontec GmbH raises €4.8m in a second closing of its Series A financing
Brings Series A total to €14.25m to advance RNA-based immunotherapeutics for cancer and viral diseases Rigontec GmbH, a privately held biopharmaceutical company developing RNA-based immunotherapeutics for the treatment of cancer and viral diseases, today announces it has raised €4.8 million in a second closing of its Series A financing round from Forbion Capital Partners, a Dutch life-sciences venture capital firm, and Sunstone Capital, a Copenhagen based venture capital investor. The new
 
Press
14. October 2014
Rigontec GmbH raises € 9.45 m in a first closing of a Series A financing round to advance RNA-based immunotherapeutics for cancer and viral diseases
Rigontec GmbH, a privately held biopharmaceutical company developing RNA-based immunotherapeutics for the treatment of cancer and viral diseases, announces the first closing of its Series A financing round, raising €9.45 million. The round was co-led by Wellington Partners and Boehringer Ingelheim Venture Fund, and included NRW Bank and High-Tech Gründerfonds (HTGF). Rigontec is developing synthetic ligands of a novel receptor of the innate immune system, Retinoic acid Inducible Gene I (RI
 

Info & Contact

Dr. Annegret de Baey-Diepolder
Phone:
+49 8341 9993464
Web:
www.rigontec.de

Address

Biomedizinisches Zentrum, Gebäude 344
Sigmund-Freud-Str. 25
53127 Bonn

In portfolio

13. Jun 2014 – 06. Sep 2017

Sector

HTGF Manager

 
Dr. Caroline Fichtner, Principal / Authorized Signatory
Exit